BCM
NKTR icon

Boxer Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Boxer Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-125,000
Closed -$7.11M – 48
2025
Q3 		$7.11M Hold
125,000
– – 2.27% 13
2025
Q2 		$3.23M Buy
+125,000
New +$1.4M 1.63% 12

Other funds holding NKTR

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boxer Capital Management's NKTR Position: Q4 2025 in Review

Boxer Capital Management sold out of Nektar Therapeutics (NKTR) in Q4 2025, closing a stake of 125,000 shares — an estimated $7.11M sold.

Boxer Capital Management first reported a position in NKTR in Q2 2025 and held it in 2 quarters. The position peaked at $7.11M in Q3 2025. 180 funds tracked by Wall St. Rank hold NKTR as of Q4 2025.

  • Boxer Capital Management reported no remaining Nektar Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Boxer Capital Management sold 125,000 Nektar Therapeutics shares in Q4 2025, an estimated $7.11M.
  • Boxer Capital Management first reported a position in Nektar Therapeutics in Q2 2025 and held it in 2 quarters.
  • Boxer Capital Management's Nektar Therapeutics position peaked at $7.11M in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2025.

Based on Boxer Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.